Table 1.
Clinical characteristics of 26 patients infected with ColR-CRKP isolates
| Clinical Characteristics | Results |
|---|---|
| Mean age (Min-Max) | 51.3 (16–86) |
| Gender | n (%) |
| Male | 16 (61.5) |
| Female | 10 (38.5) |
| Admission Unit | n (%) |
| Intensive care unit (ICU) | 9 (34.6) |
| Neurosurgical ICU | 5 (19.2) |
| Haematology ward | 3 (11.5) |
| Neurology ICU | 2 (7.7) |
| Rehabilitation medicine | 2 (7.7) |
| Respiratory ICU | 1 (3.8) |
| Emergency ICU | 1 (3.8) |
| Others | 3 (11.5) |
| Hospitalization days median (Min-Max) | 51.3 (13–231) |
| Underlying disease | n (%) |
| Brain disease | 15 (57.7) |
| Severe pneumonia | 4 (15.4) |
| Hematologic malignancy | 3 (11.5) |
| Liver disease | 2 (7.7) |
| Kidney disease | 2 (7.7) |
| Healthcare-associated infections | n (%) |
| Lower respiratory tract infection | 10 (38.5) |
| Urinary tract infection | 7 (26.9) |
| Ventilator-associated pneumonia | 4 (15.4) |
| Blood stream infection | 3 (11.5) |
| Central nervous system infection | 2 (7.7) |
| Prior exposure to antimicrobials | n (%) |
| Carbapenems | 20 (77.0) |
| beta-lactam/beta-lactamase inhibitor | 17 (65.4) |
| Polymyxin B | 14 (53.8) |
| Fluoroquinolone | 7 (26.9) |
| Cephalosporins | 7 (26.9) |
| Tigecycline | 6 (23.1) |
| Aminoglycosides | 4 (15.4) |
| Ceftazidime-avibactam | 1 (3.8) |
| Outcomes | n (%) |
| Improved | 16 (61.5) |
| Gave up | 7 (26.9) |
| Death | 3 (11.5) |